Associations of Serum Adropin Level with Severity of Coronary Artery Disease and Slow Flow in Patients with Non-ST-elevation ACS
Department of Cardiovascular,the Third Affiliated Hospital of Guangzhou Medical University,Guangzhou 510150,China
*Corresponding author:CHEN Ximing,Chief physician,Professor;E-mail:13903004891@163.com
LU Zhifeng,CHEN Ximing,WANG Shixiang. Associations of Serum Adropin Level with Severity of Coronary Artery Disease and Slow Flow in Patients with Non-ST-elevation ACS[J]. Chinese General Practice, 2020, 23(23): 2895-2900. DOI: 10.12114/j.issn.1007-9572.2020.00.327.
陆志锋,陈晞明,王世祥. 血清Adropin与急性非ST段抬高型急性冠脉综合征患者冠状动脉病变严重程度及慢血流的相关性研究[J]. 中国全科医学, 2020, 23(23): 2895-2900. DOI: 10.12114/j.issn.1007-9572.2020.00.327.
[1]BUNDHUN P K,SOOKHAREE Y,BHOLEE A,et al.Application of the SYNTAX score in interventional cardiology:a systematic review and meta-analysis[J].Medicine (Baltimore),2017,96(28):e7410.DOI:10.1097/MD.0000000000007410.
[2]KUNDU A,SARDAR P,O'DAY K,et al.SYNTAX score and outcomes of coronary revascularization in diabetic patients[J].Curr Cardiol Rep,2018,20(5):28.DOI:10.1007/s11886-018-0971-1.
[3]BUNDHUN P K,BHURTU A,HUANG F.Worse clinical outcomes following percutaneous coronary intervention with a high SYNTAX score:a systematic review and meta-analysis[J].Medicine (Baltimore),2017,96(24):e7140.DOI:10.1097/MD.0000000000007140.
[4]SHENG X C,DING S,GE H,et al.Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon[J].Int J Cardiol,2018,265:6-11.DOI:10.1016/j.ijcard.2018.04.119.
[5]CHEN Z Y,CHEN X H,LI S,et al.Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow[J].Coron Artery Dis,2015,26(2):114-120.DOI:10.1097/MCA.0000000000000179.
[6]JI H H,LI Y,FAN Z Y,et al.Monocyte/lymphocyte ratio predicts the severity of coronary artery disease:a syntax score assessment[J].BMC Cardiovasc Disord,2017,17(1):90.DOI:10.1186/s12872-017-0507-4.
[7]GHOSHAL S,STEVENS J R,BILLON C,et al.Adropin:an endocrine link between the biological clock and cholesterol homeostasis[J].Mol Metab,2018,8:51-64.DOI:10.1016/j.molmet.2017.12.002.
[8]GANESH KUMAR K,ZHANG J Y,GAO S,et al.Adropin deficiency is associated with increased adiposity and insulin resistance[J].Obesity (Silver Spring),2012,20(7):1394-1402.DOI:10.1038/oby.2012.31.
[9]ZHAO L P,XU W T,WANG L,et al.Serum adropin level in patients with stable coronary artery disease[J].Heart Lung Circ,2015,24(10):975-979.DOI:10.1016/j.hlc.2015.03.008.
[10]SATO K,YAMASHITA T,SHIRAI R,et al.Adropin contributes to anti-atherosclerosis by suppressing monocyte-endothelial cell adhesion and smooth muscle cell proliferation[J].Int J Mol Sci,2018,19(5):E1293.DOI:10.3390/ijms19051293.
[11]YU H Y,ZHAO P,WU M C,et al.Serum adropin levels are decreased in patients with acute myocardial infarction[J].Regul Pept,2014,190/191:46-49.DOI:10.1016/j.regpep.2014.04.001.
[12]冯利娟,高静.Adropin与冠心病关系的研究进展[J].天津医药,2018,46(4):444-448.DOI:10.11958/20171311.
FENG L J,GAO J.The research progress of Adropin in coronary heart disease[J].Tianjin Medical Journal,2018,46(4):444-448.DOI:10.11958/20171311.
[13]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J].中华心血管病杂志,2017,45(5):359-376.DOI:10.3760/cma.j.issn.0253-3758.2017.05.003.http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhxxgb201705003.
[14]HENDERSON R A,JARVIS C,CLAYTON T,et al.10-year mortality outcome of a routine invasive strategy versus a selective invasive strategy in non-ST-segment elevation acute coronary syndrome:the British heart foundation Rita-3 randomized trial[J].J Am Coll Cardiol,2015,66(5):511-520.DOI:10.1016/j.jacc.2015.05.051.
[15]FAROOQ V,SERRUYS P W,BOURANTAS C,et al.Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with Taxus and cardiac surgery (SYNTAX) trial[J].Eur Heart J,2012,33(24):3105-3113.DOI:10.1093/eurheartj/ehs367.
[16]盛建龙,王晓晨,许邦龙,等.冠状动脉病变SYNTAX积分影响因素分析[J].临床心血管病杂志,2015,31(3):296-298.DOI:10.13201/j.issn.1001-1439.2015.03.017.
SHENG J L,WANG X C,XU B L,et al.Influencing factors of SYNTAX score in patients with coronary heart disease[J].Journal of Clinical Cardiology,2015,31(3):296-298.DOI:10.13201/j.issn.1001-1439.2015.03.017.
[17]ORSSO C E,BUTLER A A,MUEHLBAUER M J,et al.Obestatin and adropin in Prader-Willi syndrome and nonsyndromic obesity:Associations with weight,BMI-z,and Homa-IR[J].Pediatr Obes,2019,14(5):e12493.DOI:10.1111/ijpo.12493.
[18]IGNARRO L J.Nitric oxide as a unique signaling molecule in the vascular system:a historical overview[J].J Physiol Pharmacol,2002,53(4 Pt 1):503-514.
[19]TOPUZ M,CELIK A,ASLANTAS T,et al.Plasma adropin levels predict endothelial dysfunction like flow-mediated dilatation in patients with type 2 diabetes mellitus[J].J Investig Med,2013,61(8):1161-1164.DOI:10.2310/JIM.0000000000000003.
[20]WU L Z,FANG J,CHEN L L,et al.Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients[J].Clin Chem Lab Med,2014,52(5):751-758.DOI:10.1515/cclm-2013-0844.
[21]ZHAO L P,YOU T,CHAN S P,et al.Adropin is associated with hyperhomocysteine and coronary atherosclerosis[J].Exp Ther Med,2016,11(3):1065-1070.DOI:10.3892/etm.2015.2954.
[22]DEMIRCELIK B,CAKMAK M,NAZLI Y,et al.Adropin:a new marker for predicting late saphenous vein graft disease after coronary artery bypass grafting[J].Clin Invest Med,2014,37(5):E338-344.DOI:10.25011/cim.v37i5.22014.